{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T18:26:10Z","timestamp":1694802370239},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s11940-014-0328-z","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T16:08:28Z","timestamp":1416586108000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis"],"prefix":"10.1007","volume":"17","author":[{"given":"Ruben","family":"Torres-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo F.","family":"Sanchez-Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"issue":"6","key":"328_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00055735-200212000-00006","volume":"13","author":"R Foroozan","year":"2002","unstructured":"Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002;13(6):375\u201380.","journal-title":"Curr Opin Ophthalmol"},{"key":"328_CR2","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Lapiscina E, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe A, Torres-Torres R, et al. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult Scler. 2014.","DOI":"10.1177\/1352458514542862"},{"issue":"12","key":"328_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","author":"Optic Neuritis Study Group","year":"1991","unstructured":"Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109(12):1673.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"328_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bjo.2005.085399","volume":"90","author":"J de la Cruz","year":"2006","unstructured":"de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90(5):551.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"328_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0002-9394(03)00862-6","volume":"137","author":"RW Beck","year":"2004","unstructured":"Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77\u201383.","journal-title":"Am J Ophthalmol"},{"key":"328_CR6","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"JH Noseworthy","year":"2001","unstructured":"Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514.","journal-title":"Neurology"},{"key":"328_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","volume":"64","author":"HG Roed","year":"2005","unstructured":"Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804.","journal-title":"Neurology"},{"key":"328_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","volume":"63","author":"K Ruprecht","year":"2004","unstructured":"Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081.","journal-title":"Neurology"},{"key":"328_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"G Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576.","journal-title":"Lancet"},{"key":"328_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9394(01)01209-0","volume":"132","author":"CHAMPS Study Group","year":"2001","unstructured":"CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463.","journal-title":"Am J Ophthalmol"},{"key":"328_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242.","journal-title":"Neurology"},{"key":"328_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","volume":"374","author":"G Comi","year":"2009","unstructured":"Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503.","journal-title":"Lancet"},{"key":"328_CR13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.eye.6702459","volume":"21","author":"G Heron","year":"2007","unstructured":"Heron G, Thompson KJ, Dutton GN. The symptomatic Pulfrich phenomenon can be successfully managed with a coloured lens in front of the good eye\u2014a long- term follow-up study. Eye (Lond). 2007;21:1469\u201372.","journal-title":"Eye (Lond)"},{"issue":"3","key":"328_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/practneurol-2011-000013","volume":"11","author":"G McGowan","year":"2011","unstructured":"McGowan G, Ahmed TY, Heron G, Diaper C. The Pulfrich phenomenon; clumsiness and collisions which can be ameliorated. Pract Neurol. 2011;11(3):173\u20136.","journal-title":"Pract Neurol"},{"issue":"1","key":"328_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bjo.60.1.60","volume":"60","author":"GD Perkin","year":"1976","unstructured":"Perkin GD, Rose FC. Uhthoff\u2019s syndrome. Br J Ophthalmol. 1976;60(1):60\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"13 pt 2","key":"328_CR16","first-page":"1098Y1106","volume":"70","author":"SL Davis","year":"2008","unstructured":"Davis SL, Frohman TC, Crandall CG, et al. Modelling Uhthoff\u2019s phenomenon in MS patients with internuclear ophthalmoparesis. Neurology. 2008;70(13 pt 2):1098Y1106.","journal-title":"Neurology"},{"issue":"4","key":"328_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1212\/01.CON.0000433287.30715.07","volume":"19","author":"AD Rae-Grant","year":"2013","unstructured":"Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. CONTINUUM Lifelong Learn Neurol. 2013;19(4):992\u20131006. The very latest and most comprehensive review of unusual symptoms and s\u00edndromes. in MS; essential reading.","journal-title":"CONTINUUM Lifelong Learn Neurol"},{"key":"328_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/archopht.1993.01090020085029","volume":"111","author":"JL Keltner","year":"1993","unstructured":"Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111:231\u20134.","journal-title":"Arch Ophthalmol"},{"key":"328_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.42.1.68","volume":"42","author":"GT Plant","year":"1992","unstructured":"Plant GT, Kermode AG, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology. 1992;42:68\u201376.","journal-title":"Neurology"},{"issue":"4","key":"328_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.pmr.2013.06.002","volume":"24","author":"CE Francis","year":"2013","unstructured":"Francis CE. Visual issues in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):687\u2013702.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"328_CR21","first-page":"455","volume":"1","author":"DS Zee","year":"1992","unstructured":"Zee DS. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin Neurol. 1992;1:455\u201370.","journal-title":"Baillieres Clin Neurol"},{"key":"328_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/jnnp.73.1.51","volume":"73","author":"EM Frohman","year":"2002","unstructured":"Frohman EM, Frohman TC, O\u2019Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry. 2002;73:51\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"328_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00415-003-1038-8","volume":"250","author":"A Serra","year":"2003","unstructured":"Serra A, Derwenskus J, Downey DL, et al. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250:569\u201375.","journal-title":"J Neurol"},{"key":"328_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1600-0404.2004.00278.x","volume":"110","author":"I Bolanos","year":"2004","unstructured":"Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand. 2004;110:161\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"328_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","volume":"4","author":"EM Frohman","year":"2005","unstructured":"Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111\u201321.","journal-title":"Lancet Neurol"},{"issue":"3","key":"328_CR26","first-page":"267","volume":"I","author":"A Niestroy","year":"2007","unstructured":"Niestroy A, Rucker JC, Leigh RJ. Neuro-ophthalmologic aspects of multiple sclerosis: using eye movements as a clinical and experimental tool. Clin Ophthalmol. 2007;I(3):267\u201372.","journal-title":"Clin Ophthalmol"},{"key":"328_CR27","first-page":"1409","volume":"4","author":"J Graves","year":"2010","unstructured":"Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol. 2010;4:1409\u201322. A full update of the visual manifestations of multiple sclerosis and its management. Recommended reading.","journal-title":"Clin Ophthalmol"},{"key":"328_CR28","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ana.410410620","volume":"41","author":"L Averbuch-Heller","year":"1997","unstructured":"Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818\u201325.","journal-title":"Ann Neurol"},{"key":"328_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/PL00007728","volume":"244","author":"M Starck","year":"1997","unstructured":"Starck M, Albrecht H, Pollman W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9\u201316.","journal-title":"J Neurol"},{"key":"328_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11940-005-0008-0","volume":"7","author":"JC Rucker","year":"2005","unstructured":"Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol. 2005;7:69\u201377.","journal-title":"Curr Treat Options Neurol"},{"key":"328_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp.74.1.1","volume":"74","author":"RJ Leigh","year":"2003","unstructured":"Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry. 2003;74:1\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"328_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jaapos.2003.12.013","volume":"8","author":"EG Buckley","year":"2004","unstructured":"Buckley EG, Holgado S. Surgical treatment of upgaze palsy in Parinaud\u2019s syndrome. J AAPOS. 2004;8:249\u201353.","journal-title":"J AAPOS"},{"issue":"1","key":"328_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0404.1996.tb00036.x","volume":"94","author":"T Postert","year":"1996","unstructured":"Postert T, McMonagle U, Buttner T, et al. Paroxysmal convergence spasm in multiple sclerosis. Acta Neurol Scand. 1996;94(1):35\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"328_CR34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","volume":"10","author":"L Renfro","year":"1992","unstructured":"Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505\u201312.","journal-title":"Dermatol Clin"},{"issue":"3","key":"328_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin. Clin Rev Allerg Immunol. 2005;29(3):173\u201384.","journal-title":"Clin Rev Allerg Immunol"},{"issue":"3","key":"328_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0002-9394(14)70844-X","volume":"124","author":"KT Oh","year":"1997","unstructured":"Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol. 1997;124(3):416\u20138.","journal-title":"Am J Ophthalmol"},{"key":"328_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/00006982-200308000-00019","volume":"23","author":"JE Rubio","year":"2003","unstructured":"Rubio JE, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina. 2003;23:546\u20138.","journal-title":"Retina"},{"key":"328_CR38","first-page":"1077","volume":"119","author":"R Tokai","year":"2001","unstructured":"Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"328_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/01.wnl.0000257109.61671.06","volume":"68","author":"JA Cohen","year":"2007","unstructured":"Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007;68(12):939\u201344.","journal-title":"Neurology"},{"issue":"3","key":"328_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"G Comi","year":"2001","unstructured":"Comi G, Filippi M, Wolinsky JS, et al. European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290\u20137.","journal-title":"Ann Neurol"},{"key":"328_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"328_CR42","unstructured":"Highlights of prescribing information: Gilenya (fingolimod) capsules. Novartis. 2012."},{"issue":"4","key":"328_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438\u201346.","journal-title":"Lancet Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-014-0328-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0328-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:59:57Z","timestamp":1659095997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-014-0328-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s11940-014-0328-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,18]]},"assertion":[{"value":"18 November 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"328"}}